alphav Vitronectin receptors in vascular-mediated disorders.
Various integrin antagonist candidates including antibodies, cyclic peptides, peptidomimetics, and non-peptides have been clinically evaluated and shown to successfully modulate certain disease processes. This review will focus on the key role of the alphav integrin (alphavbeta3 and alphavbeta5) in vascular disorders such as restenosis and angiogenesis-mediated disorders.
Mousa
Shaker A
SA
Albany College of Pharmacy, Albany, New York 12208-3942, USA. Mousas@acp.edu
D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000502:physiology*; D016023:Integrins / Q000502:physiology*; D019030:Receptors, Vitronectin / Q000502:physiology*; D014652:Vascular Diseases / Q000503:physiopathology* / Q000601:surgery
D039302:Integrin alphaVbeta3; D016023:Integrins; D019030:Receptors, Vitronectin; C064660:integrin alphaVbeta5